Aditxt Stock Soars 14.93% on Nasdaq Compliance

Aditxt's stock surged by 14.93% in pre-market trading on April 11, 2025, marking a significant rise in its share price.

Aditxt, Inc. has successfully regained compliance with Nasdaq's minimum bid price requirement, which had previously led to a scheduled hearing on April 22, 2025. This compliance has resulted in the cancellation of the hearing, allowing the company's stock to continue trading without interruption.

The company's stock had experienced a decline in recent days, shedding 8.81% on Wednesday, April 9, 2025, despite the positive news of regaining compliance. This decline was part of a broader market trend where several biopharmaceutical stocks faced losses amid a lack of fresh developments to drive investor interest.

In addition to regaining compliance, Aditxt has entered into a financial agreement with Evofem Biosciences, investing $1.5 million in exchange for a convertible note and a warrant to acquire shares. This investment aligns with the companies' planned merger strategy, which has been in development since March 23, 2025.